Navigation Links
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
Date:4/9/2013

rom an academic idea to preclinical proof-of-concept and there's a reasonably high probability that the company's development programs will result in new therapeutics for patients with difficult-to-treat tumors," said Larry Lasky , Ph.D., partner at US Venture Partners and Cleave director.

Cleave's lead program is discovering small molecules that target p97, a central player in the ubiquitin proteasome and autophagy pathways that are intimately involved in controlling protein degradation. Targeting protein degradation has been validated by the commercial success of VELCADE® (bortezomib) and KYPROLIS® (carfilzomib) in multiple myeloma. P97 inhibition is a novel approach that has the potential to treat a wide range of cancers.

"Cleave Biosciences has made substantial progress in identifying and optimizing small molecules against a number of novel targets and is progressing its lead program toward the clinic," said Dr. Garland. "We are pleased to join Cleave's investor syndicate to help fuel the company's momentum."

Dr. Garland and his colleagues at NEA, one of the world's largest and most active venture capital firms, have a long track record of partnering with companies that have pioneered transformative innovations in healthcare. Prior to NEA, in addition to clinical practice at the University of California, San Francisco (UCSF), Dr. Garland was with McKinsey & Company's Pharmaceutical & Medical Products and Corporate

Finance & Strategy practices. Dr. Garland completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF, and received his M.B.A. and M.P.H. from the University of California, Berkeley, his M.D. from Baylor College of Medicine and his B.S. in Electrical Engineering/Bioengineering from Rice University.

About Cleave Biosciences

Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cance
'/>"/>

SOURCE Cleave Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... leading to strong heart fitness can delay a man,s onset ... new study suggests. Blood pressure naturally increases as people ... But men with strong cardio-fitness don,t start drifting toward high ... sedentary men usually experience the early signs of high blood ...
(Date:9/16/2014)... 15, 2014Mobility is equally preserved in cancer patients suffering ... single dose of 10 Gy of radiation therapy (RT), ... 4 Gy of RT each, according to research presented ... 56th Annual Meeting. , Malignant spinal cord compression ... bone involvement that occurs when a tumor,s secondary deposit ...
(Date:9/16/2014)... some of Australia,s best fast bowlers, track and field ... thanks to a new training technique discovered by a ... of Health and Biomedical Innovation, with support from the ... Sport Science Research, has studied the run-ups of elite ... jump and pole vault and found the vertical objects ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... Transparency Market Research, a U.S. - ... care market is expected to report an approximate value ... Care Market (By Product Type - Skin Whitening/ Lightening ... and Masks and Others (fade creams, pore strips and ... Forecast 2013 – 2019,’ is now available for sale ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Getting the jump on competitors: QUT study 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... Brunswick are facing one of the worst gastroenteritis epidemics ... gear, with patients coming// in droves for relief. The ... continue for a few days but seldom endangers life. ... greater Montreal area have reported the viral outbreak. Dr. ...
... nutrient folate through both diet and supplements may have ... a report in the January issue of Archives of ... year 2047, the prevalence of Alzheimer’s disease is expected ... Delaying the onset of this neurodegenerative disease would significantly ...
... fight malaria in Africa has received its first-ever challenge ... pledge// to match dollar for dollar up to $3 ... a disease that kills more than 1 million people ... ‘Nothing But Nets’ campaign, a partnership between the UN ...
... Welcome to another cold season. If you’re like most adults, ... especially preschoolers, have it worse//, getting as many as eight ... Mayo Clinic Women’s HealthSource offers insights on how you can ... ,It’s a virus, not the temperature, that causes colds. ...
... to improve the treatment given to people bitten by snakes or ... ,Africa, Latin America and Asia are the most affected ... it comes to snake bite, the actual number of death is ... intervention. ,According to a WHO release, rabies figures tenth ...
... disease. Yet recent studies have shown that the chance of ... and exercise//, the chances of surviving it, also depend on ... putting around 50,000 pounds behind a study to be carried ... will involve cancer survivors aged above fifty and with a ...
Cached Medicine News:Health News:Higher Folate Levels Linked to Reduced Risk for Alzheimer’s Diseas 2Health News:Yes, Chicken Soup Can Help 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: